¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Tissue Cell"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • inflammatory cell
    ¿°Áõ¼¼Æ÷
  • infundibular cell
    ±ò¶§±â¼¼Æ÷, ´©µÎ¼¼Æ÷
  • inner cell mass
    ¼Ó¼¼Æ÷µ¢ÀÌ, ³»¼¼Æ÷±«
  • intercalated cell
    »çÀ̼¼Æ÷, °³Àç¼¼Æ÷
  • interdental cell
    û°¢Ä¡¾Æ»çÀ̼¼Æ÷, Ä¡°£¼¼Æ÷
  • intermediate cell mass
    Áß°£¼¼Æ÷µ¢ÀÌ, Áß°£¼¼Æ÷±«
  • interstitial cell
    »çÀÌÁú¼¼Æ÷, °£Áú¼¼Æ÷
  • interstitial cell-stimulating hormone
    »çÀÌÁú¼¼Æ÷ÀÚ±ØÈ£¸£¸ó, °£Áú¼¼Æ÷ÀÚ±ØÈ£¸£¸ó
  • interstitial plasma cell pneumonia
    »çÀÌÁúÇüÁú¼¼Æ÷Æó·Å, ÆóÆ÷ÀÚÃæÁõ
  • Jurkat cell
    Àúı¼¼Æ÷
  • juvenile cell
    À¯¾à¼¼Æ÷
  • juxtaglomerular cell tumor
    Å丮°ç¼¼Æ÷Á¾¾ç, »ç±¸Ã¼¿·¼¼Æ÷Á¾¾ç
  • Kupffer¡¯s cell
    ÄíÆÛ¼¼Æ÷, º°Å«Æ÷½Ä¼¼Æ÷
  • killer cell
    »ìÇØ¼¼Æ÷
  • Langerhans cell
    ¶û°Ô¸£Çѽº¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • islet cell carcinoma
    ¼¶¼¼Æ÷¾ÏÁ¾
  • juvenile cell
    À¯¾à¼¼Æ÷
  • killer cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
  • Kupffer¡¯s cell
    º°Å«Æ÷½Ä¼¼Æ÷, ÄíÆÛ¼¼Æ÷
  • lacunar cell
    °ø°£¼¼Æ÷
  • large cell carcinoma
    Å«¼¼Æ÷¾ÏÁ¾, ´ë¼¼Æ÷¾ÏÁ¾
  • lepra cell
    ³ªº´¼¼Æ÷
  • leukemic cell
    ¹éÇ÷º´¼¼Æ÷
  • light cell
    ¹àÀº¼¼Æ÷
  • lipoid cell
    ÁöÁú¼¼Æ÷
  • luteal cell
    Ȳü¼¼Æ÷
  • lymphoid cell
    ¸²ÇÁ°è¼¼Æ÷, ¸²ÇÁ¸ð¾ç¼¼Æ÷
  • lymphokine-activated killer cell
    ¸²Æ÷Ä«ÀÎȰ¼º¼¼Æ÷µ¶¼º¼¼Æ÷
  • lymphopoietic cell
    ¸²ÇÁ±¸»ý¼º¼¼Æ÷
  • marrow cell
    °ñ¼ö¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • heart failure cell
    ½ÉºÎÀü¼¼Æ÷(¡­á¬øà)
  • helmet cell
    Åõ±¸¼¼Æ÷
  • helper T cell
    Á¶·ÂT¼¼Æ÷, º¸Á¶T¼¼Æ÷
  • helper T cell
    º¸Á¶ T¼¼Æ÷
  • helper T cell
    º¸Á¶ T ¼¼Æ÷
  • helper cell
    º¸Á¶¼¼Æ÷
  • helper cell
    Á¶·Â¼¼Æ÷, º¸Á¶¼¼Æ÷
  • helper cell activity
    Á¶·Â¼¼Æ÷´É, º¸Á¶¼¼Æ÷´É
  • hematopoietic cell transplantation
    Á¶Ç÷¼¼Æ÷À̽Ä(¡­á¬øàì¹ãÕ)
  • hematopoietic stem cell
    Á¶Ç÷°£¼¼Æ÷
  • hemolytic plaque-forming cell
    ¿ëÇ÷¹Ý Çü¼º¼¼Æ÷, ¿ëÇ÷ÇöóÅ© Çü¼º¼¼Æ÷
  • hensens cell
    ¹Ù±ù°æ°è¼¼Æ÷
  • hepatic cell
    °£¼¼Æ÷(ÊÜá¬øà).
  • hepatic cell cord
    °£¼¼Æ÷ÁÙ, °£¼¼Æ÷»è(¡­ßã).
  • heteroploid cell line
    À̼öü¼¼Æ÷°è
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • tissue inhibitor of metalloprotainase
  • tissue inhibitor of metalloproteinase
    ±Ý¼Ó´Ü¹éºÐÇØÈ¿¼Ò
  • tissue inhomogeneity
    Á¶Á÷ºñ±ÕÁú¼º
  • tissue injury
    Á¶Á÷»óÇØ(¡­ß¿úª), Á¶Á÷¼Õ»ó(¡­áßß¿)
  • tissue interaction
    Á¶Á÷°£ÀÇ »óÈ£ ÀÛ¿ë
  • tissue interactions
    Á¶Á÷°£ (ðÚòÄÊà)ÀÇ »óÈ£ÀÛ¿ë (ßÓû»íÂéÄ)
  • tissue iron
    Á¶Á÷ö(ðÚòÄôÑ)
  • tissue marker
    Á¶Á÷Ç¥ÁöÀÚ
  • tissue maximum ratio, TMR
    Á¶Á÷ÃÖ´ë¼±·®ºñ
  • tissue metabolism
    Á¶Á÷´ë»ç(¡­ÓÛÞó).
  • tissue metamorphosis
    Á¶Á÷º¯ÅÂ(¡­Ü¨÷¾)
  • tissue of neural crest (mesectoderm)
    ½Å°æ´É¼±Á¶Á÷ (Áß°£¿Ü¹è¿±)
  • tissue parasite tests
  • tissue phase
    Á¶Á÷»ó(ðÚòÄßÓ).
  • tissue plasminogen activation
    Á¶Á÷ ÇöóÁî¹Ì°Õ Ȱ¼º
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • Oxyphilic cell
    È£»ê¼º¼¼Æ÷
    [¿¾ ¿ë¾î] »êÈ£¼º¼¼Æ÷
  • Lutein cell
    Ȳ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] Ȳü¼¼Æ÷
  • Sensory cell
    °¨°¢¼¼Æ÷
    [¿¾ ¿ë¾î] °¨°¢¼¼Æ÷
  • Rod cell
    ¸·´ë¼¼Æ÷
    [¿¾ ¿ë¾î] °£»óü½Ã¼¼Æ÷
  • Mucous neck cell
    ¸ñÁ¡¾×¼¼Æ÷
    [¿¾ ¿ë¾î] Á¡¸·°æ¼¼Æ÷
  • Smooth muscle cell
    ¹Î¹«´Ì±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] ÆòȰ±Ù¼¼Æ÷
  • Hensen`s cell
    ¹Ù±ù°æ°è¼¼Æ÷
    [¿¾ ¿ë¾î] ¿Ü°æ°è¼¼Æ÷
  • M ller cell
    ºÎê»ì¾Æ±³¼¼Æ÷
    [¿¾ ¿ë¾î] ¹æ»ç±³¼¼Æ÷
  • Pole of cell
    ¼¼Æ÷±Ø
    [¿¾ ¿ë¾î] ¼¼Æ÷±Ø
  • Cell cycle
    ¼¼Æ÷ÁÖ±â
    [¿¾ ¿ë¾î] ¼¼Æ÷ÁÖ±â
  • Border cell
    ¼Ó°æ°è¼¼Æ÷
    [¿¾ ¿ë¾î] ³»°æ°è¼¼Æ÷
  • Goblet cell
    ¼úÀܼ¼Æ÷
    [¿¾ ¿ë¾î] ¹è»ó[Á¡¾×]¼¼Æ÷
  • Neurosensory cell
    ½Å°æ°¨°¢¼¼Æ÷
    [¿¾ ¿ë¾î] ½Å°æ°¨°¢¼¼Æ÷
  • Neurosensory cell body
    ½Å°æ°¨°¢¼¼Æ÷ü
    [¿¾ ¿ë¾î] ½Å°æ°¨°¢¼¼Æ÷ü
  • Nerve cell [Neuron]
    ½Å°æ¼¼Æ÷ [½Å°æ´ÜÀ§]
    [¿¾ ¿ë¾î] ½Å°æ¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
PPT parietal pleural tissue; partial prothrombin time; peak-to-peak threshold; Pfeiffer-Palm-Teller [syn...
QCO2 carbon dioxide evolution by a tissue
rh-tPA recombinant tissue plasminogen activator
RSTS retropharyngeal soft tissue space
RTG-2 rainbow trout gonadal tissue cells
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
t-PA tissue PA
TC tissue culture
TCID(50) tissue culture infectious dose
TCID50 tissue culture infective dose
TCM tissue culture medium
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • foreign body giant cell
    À̹° °Å´ë ¼¼Æ÷, À̹° °Å¼¼Æ÷
  • hair cell
    ¸ð ¼¼Æ÷
  • hairy cell leukemia
    À¯¸ð»ó ¼¼Æ÷¼º ¹éÇ÷º´
  • helper cell activity
    ÇïÆÛ ¼¼Æ÷ Ȱ¼º
  • heterotrophic cell
    Á¾¼Ó ¿µ¾ç ¼¼Æ÷
    ¿µ¾ç¿øÀ¸·Î¼­ À¯±â¹°À» ÇÊ¿ä·Î ÇÏ´Â ¼¼Æ÷.
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human t-cell leukemia virus
    ÀÎü T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • Hurthle cell
    Hurthle ¼¼Æ÷
    dzºÎÇÑ ¼¼Æ÷Áú³» ¸¹Àº È£»ê¼º °ú¸³À» ÇÔÀ¯.
  • huthle cell adenoma
    ÈÖ¸£Æ®·¹ ¼¼Æ÷ ¼±Á¾, Huthle ¼¼Æ÷ ¼±Á¾
  • hypercomplex cell
    Ãʺ¹ÇÕ ¼¼Æ÷
  • hypoxic cell sensitizer
    Àú»ê¼Ò ¼¼Æ÷ °¨ÀÛÁ¦
  • immunocompetent foreign lymphoid cell
    ¿ÜºÎ ¸é¿ªÀû°Ý ÀÓÆÄ°è ¼¼Æ÷
  • immunologically committed cell
    ¸é¿ª °æÇè ¼¼Æ÷
  • immunologically performing cell
    ¸é¿ª ¼öÇà ¼¼Æ÷
  • inflammatory cell infiltration
    ¿°Áõ ¼¼Æ÷ÀÇ Ä§À±
    ¿°ÁõÀ» ÀÏÀ¸Å°¸é »ýü´Â ¹æ¾îÀûÀ¸·Î Ȱµ¿ÇÏ°í ¿°Áõ ¹°ÁúÀÇ Á¦°Å, ¿°ÁõÀÇ ÁøÀüÀ» ÀúÁöÇϱâ À§ÇØ ÁÖ·Î Ç÷¾×ÁßÀÇ ¹éÇ÷±¸
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
carcinoma, basal cell A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs.
(12 Dec 1998)
carcinoma, giant cell An epithelial neoplasm characterised by unusually large anaplastic cells. It is highly malignant with fulminant clinical course, bizarre histologic appearance and poor prognosis. It is most common in the lung and thyroid.
(12 Dec 1998)
carcinoma, islet cell A carcinoma of the islets of langerhans.
(12 Dec 1998)
carcinoma, large cell A tumour of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic.
(12 Dec 1998)
carcinoma, merkel cell A carcinoma arising from merkel cells located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of merkel cell carcinoma, occurring generally in elderly patients.
(12 Dec 1998)
carcinoma, non-small-cell lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. They are dealt with collectively because of the shared properties of poor response to conventional chemotherapy and the potential for cure with surgical resection in a fraction of patients.
(12 Dec 1998)
carcinoma, renal cell Carcinoma of the renal parenchyma usually occurring in middle age or later and composed of tubular cells in varying arrangements. It was first described in 1826. Possible causal factors are environmental, hormonal, cellular, and genetic. Smoking is a definite risk factor and obesity is associated with increased risk. Renal cell carcinoma accounts for approximately 3% of adult cancer; the male-female ratio is 2:1. It is more common among urban residents than rural.
(12 Dec 1998)
carcinoma, signet ring cell A highly malignant, mucus-secreting tumour in which the mucus-secreting cells are anaplastic and appear rounded, with the nucleus displaced to one side by a globule of mucus in the cytoplasm.
(12 Dec 1998)
carcinoma, small cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterised by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. There are admixtures of small cell lung carcinoma with other types of lung cancer. Small cell carcinomas are distinguished by their distinctive biological features, response to chemotherapy and radiotherapy, and by their nearly universal tendency to develop overt or subclinical metastases, which frequently eliminates surgery in most patients.
(12 Dec 1998)
carcinoma, squamous cell A carcinoma derived from stratified squamous epithelium. It may also occur in sites where glandular or columnar epithelium is normally present.
(12 Dec 1998)
carcinoma, transitional cell A malignant neoplasm derived from transitional epithelium, occurring chiefly in the urinary bladder, ureters or renal pelves (especially if well differentiated), frequently papillary. Transitional cell carcinomas are graded 1 to 3 or 4 according to the degree of anaplasia, grade 1 appearing histologically benign but being liable to recurrence.
(12 Dec 1998)
cardiac cell Strictly speaking any cell of or derived form the cardium of the heart, but often used loosely of heart cells.
(18 Nov 1997)
packed cell volume <haematology> Measurement of the proportion of the blood occupied by the red blood cells. Normal values are 40-54% in males, 35-47% in females.
(13 Nov 1997)
packed red blood cell <haematology> Red blood cells collected from one individual that are packed into a small volume for transfusion into a patient.
(16 Dec 1997)
macroglia cell <pathology> A glial cell found in vertebrate brain, named for its characteristic star like shape.
Astrocytes lend both mechanical and metabolic support for neurons, regulating the environment in which they function.
See: oligodendrocytes.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
ÅëÇÕ°Ë»ö ¿Ï·á